AstraZeneca might have to address questions about its potential to expand profitability next year when it reports second-quarter results, Bank of America analysts say in a research note. The U.K. drugmaker is expected to report quarterly sales of $15.4 billion and core earnings per share of $2.51, according to Bank of America. AstraZeneca is likely to reiterate guidance for 2026, but the debate about its 2027 profit margin might kick off again, the analysts says. Consensus expectations point to a 160 basis-point expansion in AstraZeneca's core operating profit margin, but Bank of America is more cautious even if its sales estimate is above consensus, the analysts add. Shares fall 0.6%. (adria.calatayud@wsj.com)